Pharma Focus Europe

Beactica Therapeutics Welcomes Dr. Jarl Ulf Jungnelius to Its Board of Directors as the Company Progresses Towards Clinical-stage Activities

Monday, June 19, 2023

We are pleased to announce the addition of Dr. Jarl Ulf Jungnelius to the Board of Directors of Beactica Therapeutics," said Dr. Per Källblad, CEO of Beactica Therapeutics. "Dr. Jungnelius brings a wealth of experience in the clinical development of oncology drugs from his extensive career at prominent pharmaceutical companies. His expertise will be instrumental as Beactica advances its strategic plan to become a clinical-stage company.

Dr. Jarl Ulf Jungnelius is a licensed medical practitioner and board-certified oncologist with over 25 years of clinical and research experience. He has held key positions at various renowned organizations, including Celgene, where he served as Vice President of Clinical Research and Development, Solid Tumors, from 2007 to 2014. In addition to Celgene, he has also contributed to the success of oncology programs at Takeda, Pfizer, and Eli Lilly & Company. Dr. Jungnelius has played a significant role in the clinical development of several groundbreaking oncology drugs such as gemcitabine (Gemzar®), premetrexed (Alimta®), sunitinib (Sutent®), lenalidomide (Revlimid®), and the albumin-bound nanoparticle paclitaxel (Abraxane®). Currently, he serves as the Senior Oncology Advisor for TME Pharma and sits on the boards of Oncopeptides AB, Biovica International AB, Ryvu Therapeutics, and HealthCom GmbH. Dr. Jungnelius holds a Bachelor of Science degree and an M.D. from the Karolinska Institute in Stockholm, Sweden.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva